95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s robotics platform grows thousands of human tissues daily, directly tackling the biological gap behind ...

Andrei Georgescu, PhD, CEO of Vivodyne, was hoping to couple his interests in science and engineering when he chose UPenn for his graduate research. His goal was to build on his background in ...

PHILADELPHIA--(BUSINESS WIRE)--Vivodyne, a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, today announced the ...

Vivodyne, a startup that aims to use an AI and robotics platform to grow human tissue and streamline the inefficient and challenging animal testing process for drug discovery, has announced that it ...

Philadelphia-based AI-enabled biotech company Vivodyne announced it closed a $38 million seed funding round led by Khosla Ventures. CS Ventures, Kairos Ventures, Bison Ventures and MBX Capital also ...

Vivodyne has launched with $38 million in seed funding, led by the investment firm Khosla Ventures, to discover and develop drugs by testing them on lab-grown human organs. The Philadelphia-based ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Vivodyne's platform is designed ...

A University of Pennsylvania-founded biotech company that helps scientists test drugs and therapeutics has raised $4 million in order to more widely adopt their platform that embraces “organs on chip” ...

Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. Only about 10% of drugs in development ever make it to market.

WASHINGTON--(BUSINESS WIRE)--Dr. Jane Goodall, DBE, UN Messenger of Peace and Founder of the Jane Goodall Institute, a conservation organization focused on environmental and humanitarian education, ...

Vivodyne Chief Operating Officer Julie O'Shaughnessy (L) and Vivodyne CEO Andrei Georgescu (R). 95% of clinical trials fail because animal testing is no substitute for human biology - Vivodyne’s ...